MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.carrev.2026.08.020

Медицинская библиотека · Cardiovascular revascularization medicine : including molecular interventions · 2026

Targeting inflammation to prevent conduction injuries following TAVI: A systematic review and meta-analysis of glucocorticoid therapy.

Suruagy-Motta Ricardo F O, Calheiros Caio de Omena S, Silva Júlia Agra, Borges Marcela Caracas Machado, Freitas Déborah Eloyse Santos, Vieira Laila Leite Pacheco, Aguiar-Barros Ana Beatriz P, Firmino Maria Morena Rocha, de Moraes Saulo Rodrigo Ramalho, Filho Alfredo Aurélio Marinho Rosa, Dall'Orto Clarissa, Fernandes João Ricardo Cordeiro, Cervone Alberto Colella, Filho Evandro Martins, Stone Gregg W

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Cardiac conduction disturbances are common after transcatheter aortic valve implantation (TAVI) and frequently require permanent pacemaker implantation (PPI), associated with worse outcomes. Glucocorticoids have been proposed to reduce conduction injury by limiting inflammation and edema.

AIMS: To assess whether peri-procedural glucocorticoid therapy reduces conduction complications compared to standard care in TAVI patients.

METHODS

Systematic review and meta-analysis following Cochrane Handbook and PRISMA 2020 guidelines. PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library were searched through 2026. Randomized controlled trials and observational studies evaluating peri-procedural glucocorticoids in adults undergoing TAVI were included. Random-effects models estimated pooled risk ratios (RRs) with 95% confidence intervals (CIs).

RESULTS

Nine studies (8841 patients) were analyzed. Glucocorticoid therapy did not reduce pacemaker implantation (RR 0.91, 95% CI 0.73-1.14), new-onset left bundle branch block (RR 0.94, 95% CI 0.71-1.24), or acute kidney injury (RR 1.10, 95% CI 0.69-1.74). Mortality did not differ between groups (RR 0.94, 95% CI 0.61-1.45). Conversely, glucocorticoids were associated with increased bleeding (RR 1.39, 95% CI 1.01-1.90) and vascular complications (RR 1.86, 95% CI 1.36-2.55).

CONCLUSION

Peri-procedural glucocorticoid therapy does not reduce conduction-related complications following TAVI and is associated with increased bleeding and vascular complications. These findings suggest caution regarding routine glucocorticoid use in contemporary TAVI practice.

Для цитирования: Suruagy-Motta Ricardo F O, Calheiros Caio de Omena S, Silva Júlia Agra, Borges Marcela Caracas Machado, Freitas Déborah Eloyse Santos, Vieira Laila Leite Pacheco, Aguiar-Barros Ana Beatriz P, Firmino Maria Morena Rocha, de Moraes Saulo Rodrigo Ramalho, Filho Alfredo Aurélio Marinho Rosa, Dall'Orto Clarissa, Fernandes João Ricardo Cordeiro, Cervone Alberto Colella, Filho Evandro Martins, Stone Gregg W. Targeting inflammation to prevent conduction injuries following TAVI: A systematic review and meta-analysis of glucocorticoid therapy.. Cardiovascular revascularization medicine : including molecular interventions. 2026. DOI: 10.1016/j.carrev.2026.08.020.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.